JATT III Acquisition Corp. (NASDAQ:JTTT) announced the pricing of its $60 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “JTTT” on Wednesday, August 26, 2026.
The new SPAC aims to combine with a target company in the healthcare industry with a primary emphasis on biotechnology.
JATT III Acquisition Corp. is to be led by Chairman and Chief Executive Offier Dr. Someit Sidhu and Chief Financial Officer Nicholas Fernandez. Verender S. Badial, Christopher Staral, Dr. Arjun Goyal, and Dr. Jonthon Kluft will serve on its Board of Directors.
Total SPAC deal count for 2026 year-to-date is now 145. This offering is expected to close on Thursday, August 27, 2026.
Guggenheim Securities, LLC is acting as sole book-running manager. Greenberg Traurig LLP is serving as Issuer’s Counsel with Davis Polk & Wardwell LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Odyssey Transfer and Trust Company is acting as trustee.
